ERVW-1 and neoplasm: While we have initially proven that our prototype vaccine expressing wt ERV antigens was effective against small growing tumours, mutation of the vaccine’s ISD is needed to overcome the Env-related lack of immunogenicity and effectively clear more aggressive and developed cancers in combinational therapy.